TORONTO, March 22, 2019 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that it has been informed by Health Canada that the Company will receive a Notice of Deficiency (“NOD”) with respect to its New Drug Submissions of two cardiovascular products for which the Company has exclusive distribution rights in Canada.
“We are disappointed to learn that we will receive a NOD from Health Canada for the regulatory submissions of these two cardiovascular products,” said René Goehrum, President and CEO of BioSyent, “as these products have been approved throughout Europe and in other countries around the world. We will work towards providing Health Canada the necessary additional information it has requested for these products.”
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.
As of the date of this press release, the Company has 14,382,815 common shares issued and outstanding.
For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.
For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Web: www.biosyent.com
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.